The Product of Nature Doctrine: A Plain-English Guide to What You Can (and Can't) Patent

LEGAL DISCLAIMER: This article provides general, informational content for educational purposes only. It is not a substitute for professional legal advice from a qualified attorney. Always consult with a lawyer for guidance on your specific legal situation.

Imagine you're walking on a beach and find a one-of-a-kind, breathtakingly beautiful seashell. It's unique, valuable, and you were the first to discover it. Can you get a `patent` on it? The answer is a clear “no.” The seashell is a product of nature. You didn't create it; you merely found it. Now, imagine you take that seashell, grind it into a fine, iridescent powder, and mix it with a special polymer you invented to create a revolutionary, super-durable, and shimmering new paint. Can you patent that paint? Very likely, yes. You have taken a natural product and transformed it into something new, with “markedly different characteristics” from the original shell. This simple story is the heart of the product of nature doctrine. It's a fundamental rule in U.S. `patent_law` that says you cannot own a piece of the natural world itself—be it a mineral, a plant, a law of physics, or even your own DNA. But you *can* patent a new and useful invention derived from it, as long as your human ingenuity has made it significantly different from what is found in nature.

• Key Takeaways At-a-Glance:
• The Core Principle: The product of nature doctrine is a legal rule, created by courts, that prohibits granting a patent for discoveries of things that already exist in nature, such as physical phenomena, laws of nature, or living organisms. patent_eligibility.
• Your Real-World Impact: This doctrine directly affects inventors, scientists, and businesses, especially in fields like biotechnology, pharmaceuticals, and software. It draws the critical line between a non-patentable discovery and a patentable invention.
• The Critical Hurdle: To secure a patent and overcome the product of nature doctrine, you must prove your creation has “markedly different characteristics” with the potential for a “new utility” compared to its natural counterpart. intellectual_property.

The product of nature doctrine wasn't written into law by Congress. Instead, it was sculpted over more than a century by judges grappling with a single, profound question: Where does nature's handiwork end and human invention begin? Its roots trace back to the very foundation of U.S. patent law, which was designed to encourage innovation, not reward observation. Early on, the line was relatively clear. No one tried to patent a new type of rock or a species of bird they discovered. The first major challenge came with the rise of modern chemistry and biology. In a 1911 case, `parke-davis_v_mulford`, the brilliant chemist who first isolated and purified adrenaline from animal glands was granted a patent. The court reasoned that the purified adrenaline, separated from the body's other tissues and made stable for medical use, was a new “composition of matter” and not merely a product of nature. For the first time, it was commercially useful and distinct from its natural state. This “purification” theory held for decades. The line was tested again in `funk_brothers_seed_co_v_kalo_inoculant_co` (1948). An inventor discovered that certain species of root-nodule bacteria helped plants, but they naturally inhibited each other. He found a combination of strains that did not have this inhibitory effect and patented the mixture. The `supreme_court` struck down the patent. They argued that the inventor “did not create a state of non-inhibition in the bacteria.” He had simply discovered a natural principle and packaged together naturally occurring organisms. This was the “work of nature,” not invention. The pendulum swung back toward inventors with the dawn of the biotech age. The landmark 1980 case of `diamond_v_chakrabarty` involved a genetically engineered bacterium capable of breaking down crude oil. The `uspto` rejected the patent, arguing that living things were not patentable. In a monumental decision, the Supreme Court disagreed, famously stating that “anything under the sun that is made by man” could be patented. Since Chakrabarty's bacterium was genetically modified and had characteristics not found in nature, it was a patentable invention. This decision kicked the door open for the modern biotechnology industry. This set the stage for the ultimate confrontation in the 21st century: the patenting of human genes. This battle culminated in the 2013 Supreme Court case `association_for_molecular_pathology_v_myriad_genetics`, which we will explore in detail in Part 4.

The primary law governing what can be patented is found in Title 35 of the U.S. Code. Specifically, it's one critical sentence: 35_usc_101: “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.” On its face, this language seems incredibly broad. But federal courts have established three major “judicial exceptions” to this rule. These are things Congress never explicitly wrote down, but which courts have determined are implicitly excluded from patentability to prevent monopolizing the basic tools of science and technology. The three exceptions are:

• Laws of Nature: Think of Einstein's E=mc² or the law of gravity. These are fundamental truths about the universe. Granting a patent on one would prevent others from using that basic knowledge.
• Natural Phenomena: This includes discoveries of things that physically exist in nature, like a new mineral, a new plant, or a previously unknown celestial body. This is the category where the product of nature doctrine lives.
• Abstract Ideas: These are concepts like mathematical formulas, algorithms in their purest form, or methods of organizing human activity (like a new way to run an auction).

The product of nature doctrine is the court-made rule used to analyze whether something falls into the “Natural Phenomena” exception.

Patent law is territorial, meaning a U.S. patent only protects you in the United States. If you're an inventor or a business, understanding how other major economic regions handle the product of nature doctrine is critical. The approach to patenting genes and other biological material, in particular, varies significantly.

To truly understand the product of nature doctrine, you must understand the legal tests and concepts the `uspto` and courts use to apply it. The central question is always: “Is this invention something new made by a human, or is it just a newly noticed part of nature?”

The modern framework for analyzing patent eligibility, including the product of nature doctrine, largely comes from two Supreme Court cases: `mayo_collaborative_services_v_prometheus_laboratories` and `alice_corp_v_cls_bank_international`. This framework is often called the “Alice/Mayo Test.”

First, a patent examiner or court looks at the patent claim and asks if it is, at its core, about a law of nature, a natural phenomenon, or an abstract idea.

• Example (Law of Nature): A patent claim for a drug dosage based on a newly discovered correlation between a metabolite level in the blood and the drug's effectiveness. The core of the claim is the *correlation*—a law of nature.
• Example (Natural Phenomenon): A patent claim for the BRCA1 gene sequence itself. The claim is directed to the genetic information as it exists in the human body—a natural phenomenon.

If the answer is “no,” the inquiry ends, and the claim is likely patent-eligible (assuming it meets other requirements like `novelty` and `utility`). If the answer is “yes,” the analysis proceeds to the second, more critical step.

If the claim is directed to a natural product or law, the court then asks: Does the claim, as a whole, add something *more*? Is there an “inventive concept” that transforms the claim into a patent-eligible *application* of that natural law or product? This is where the crucial “markedly different” test comes into play.

This is the heart of the product of nature analysis. To be patentable, a composition of matter must have characteristics that are “markedly different” from what is found in nature. This difference can be in:

• Structure: A change in the chemical or physical structure. This is why synthetic cDNA (which lacks non-coding introns found in natural DNA) was deemed patentable in the `Myriad` case, while isolated DNA was not.
• Function: A new function or use that the natural product does not have. For example, a mixture of bacteria that performs a new function (that the individual strains do not) could potentially be patentable, avoiding the fate of the `Funk Brothers` patent.
• Properties: Other significant changes in properties, such as being more pure, stable, or effective. The purified adrenaline in the `Parke-Davis` case is the classic example. It was useful as a medicine in a way that adrenaline in the body was not.

Hypothetical Example: You discover a rare Amazonian fungus that produces a chemical with mild anti-inflammatory properties.

• Not Patentable: A claim to “The chemical compound as found in the Amazonian fungus.” This is a classic product of nature.
• Potentially Patentable: A claim to “A purified form of the chemical compound, at 99.9% purity, for use as a topical anti-inflammatory treatment.” Here, you are claiming a purified version with a new utility. You would need to prove its characteristics are markedly different from the compound in the raw fungus.
• Strongly Patentable: A claim to “A new synthetic molecule, wherein a methyl group is added to the natural chemical compound, resulting in a 10x increase in anti-inflammatory efficacy.” You have structurally altered the natural product to create something new and better. This is a classic inventive concept.

Navigating a patent application is not a solo journey. Understanding the roles of the key players is essential.

• The Inventor/Applicant: The individual or company that created the invention and is seeking patent protection. Their primary goal is to secure the broadest possible `patent_claim` to protect their `intellectual_property`.
• The `patent_attorney` or Agent: A legal professional who specializes in drafting patent applications and arguing on behalf of the inventor before the USPTO. Their job is to frame the invention in a way that highlights its novelty and inventive concept, carefully navigating doctrines like the product of nature.
• The `uspto` Patent Examiner: The government official who reviews the patent application. They are the gatekeeper, tasked with determining if the invention meets all legal requirements, including `35_usc_101`. They will issue an `office_action` (a rejection) if they believe the invention is an unpatentable product of nature.
• The Federal Courts: If a patent is rejected and appeals are exhausted, or if a granted patent is challenged, the case goes to the courts. The `court_of_appeals_for_the_federal_circuit` is a specialized court that hears most patent appeals. Ultimately, the `supreme_court_of_the_united_states` can take on cases that have a major impact on the law, as it did with `Chakrabarty` and `Myriad`.
• Public Interest & Industry Groups: Organizations like the American Civil Liberties Union (ACLU), who brought the case against Myriad Genetics, or industry groups like the Biotechnology Innovation Organization (BIO), often get involved in landmark cases to advocate for their respective positions on what should be patentable.

If your work involves discoveries from the natural world, you must be strategic from day one. Here is a step-by-step guide to help you position your discovery for the best possible outcome at the USPTO.

Before you even think about patents, ask yourself hard questions. Be honest about what you have discovered versus what you have *invented*.

• Have I just found something that already existed? Or have I created something new?
• What exactly did I do to it? Did I isolate it? Purify it? Genetically modify it? Combine it with something else?
• What can my creation do that the natural version cannot? Is it more stable, more effective, faster, or does it have an entirely new use?
• Document the answers. This initial analysis is the foundation of your patent strategy.

This is the most important step. You cannot just *say* your invention is different; you must *prove* it with data.

• Gather Empirical Evidence: Conduct experiments that compare your invention to its closest natural counterpart.
• Focus on Structure and Function: Generate data showing structural changes (e.g., through chemical analysis) and functional differences (e.g., showing your modified enzyme works twice as fast).
• Record Everything: Keep meticulous lab notebooks and records. This data will be crucial for convincing a patent examiner.

`Prior_art` is all the public knowledge that existed before you filed your patent application. A search is essential to determine if your invention is truly new (`novelty`) and not obvious. In the context of the product of nature doctrine, it also helps you understand how similar discoveries have been treated by the USPTO and the courts.

This is where a good `patent_attorney` is worth their weight in gold. How you write your `patent_claim`s is everything.

• Focus on the Application, Not the Discovery: Instead of claiming “The BRCA1 gene,” claim “A method of screening for breast cancer risk by probing a patient's DNA for the BRCA1 mutation.” You are claiming a *process* that uses the natural information.
• Claim the “Man-Made” Aspect: If you've created a synthetic version, claim that specifically. For example, “A synthetic cDNA molecule for the BRCA1 gene.”
• Use Functional Language: Describe what your invention *does* in a way that the natural product cannot. For example, “A genetically modified bacterium containing gene X, capable of producing industrial-grade insulin.”

It is now very common for patent examiners, especially in biotech and software, to issue an initial rejection based on `35_usc_101`. Do not panic. This is part of the process. Your attorney will use the evidence you gathered in Step 2 and the strategic claims from Step 4 to argue why your invention is not a product of nature but a patent-eligible application.

• `* provisional_patent_application`: A less formal, lower-cost application that allows you to claim “patent pending” status for one year. It's an excellent tool for inventors to secure an early filing date while they continue to refine their invention and seek funding.
• `* non-provisional_patent_application`: This is the formal, complete patent application that the USPTO will examine. It includes a detailed specification (a written description of the invention), drawings, and the all-important legal claims that define the scope of your `intellectual_property` protection.
• `* information_disclosure_statement` (IDS): This is a form you must submit to the USPTO listing all the `prior_art` (patents, publications, etc.) that you are aware of. You have a legal “duty of candor” to disclose this information; hiding relevant prior art can render a future patent unenforceable.

• The Backstory: Ananda Chakrabarty, a genetic engineer for General Electric, developed a bacterium that could break down components of crude oil. He intended to use it for cleaning up oil spills. The USPTO rejected his patent claim for the bacterium itself, on the grounds that living things were not patentable subject matter.
• The Legal Question: Can a live, human-made microorganism be patented under `35_usc_101`?
• The Court's Holding: Yes. In a 5-4 decision, the Supreme Court held that the bacterium was not a “hitherto unknown natural phenomenon,” but a “nonnaturally occurring manufacture or composition of matter.” It was a product of human ingenuity with characteristics not found in nature. They famously stated that patentable subject matter includes “anything under the sun that is made by man.”
• Impact on You Today: This case is the legal bedrock for the entire modern biotechnology industry. It confirmed that GMOs, synthetic life, and other engineered organisms are eligible for patent protection, incentivizing billions of dollars of investment in the field.

• The Backstory: Prometheus held patents on a method for optimizing the dosage of certain drugs. The method involved (a) administering the drug and (b) measuring the level of a metabolite in the patient's blood. The patent claims specified that if the level was above a certain threshold, the dose should be decreased, and if below, increased.
• The Legal Question: Is a method patentable if it is based on a newly discovered law of nature (the correlation between metabolite levels and drug efficacy)?
• The Court's Holding: No. The Supreme Court unanimously found the claims unpatentable. They established a two-part framework: (1) determine if the claim is directed to a law of nature, and if so, (2) determine if the claim adds a sufficient “inventive concept.” The Court found that simply instructing doctors to “apply the law” was not enough. The additional steps were considered routine and conventional.
• Impact on You Today: `Mayo` made it significantly harder to patent diagnostic methods and personalized medicine techniques. Any inventor in this space must now show that their method includes a truly novel or non-routine step beyond simply observing a natural correlation.

• The Backstory: Myriad Genetics discovered the precise location and sequence of two human genes, BRCA1 and BRCA2. Mutations in these genes dramatically increase the risk of breast and ovarian cancer. Myriad obtained patents on the isolated gene sequences themselves. This gave them a monopoly on all genetic testing for these mutations in the U.S.
• The Legal Question: Are isolated human genes patentable?
• The Court's Holding: In a unanimous decision, the Supreme Court ruled that isolated DNA is not patentable. Justice Clarence Thomas wrote that Myriad “did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.” However, the Court also held that complementary DNA (cDNA), a synthetic form of DNA created in a lab, *is* patentable because it is not naturally occurring.
• Impact on You Today: This decision had a massive, immediate impact. It invalidated Myriad's key patents, and within hours, other labs began offering BRCA testing at a fraction of the cost. For patients, it meant more access and lower prices. For inventors, it clearly marked the boundary: you cannot patent a piece of the human genome, but you can patent man-made manipulations of it.

The line between nature and invention is constantly being redrawn by new technology. The debates are fierce because the economic and social stakes are enormous.

• Personalized Medicine & Diagnostics: The shadow of the `Mayo` decision looms large. Companies are struggling to find ways to protect their investments in new diagnostic tests. How do you create an “inventive step” when your test is fundamentally about a natural correlation in the body? This debate pits patient access against the need to incentivize R&D.
• CRISPR and Gene Editing: Technologies like CRISPR allow scientists to edit genes with incredible precision. While the underlying CRISPR-Cas9 system has been the subject of its own epic patent battle, a new question is emerging: Is an organism (a plant, animal, or even a human cell line) that has had its native DNA edited, but not had foreign DNA inserted, still a “product of nature”? The legal arguments are just beginning.
• The Microbiome: We are just starting to understand the complex ecosystem of bacteria in our bodies. Inventions based on transplanting or altering this microbiome are promising. But `Funk Brothers` stands as a warning: is a carefully selected cocktail of natural bacteria a patentable invention or just a packaging of natural products?

• Synthetic Biology: Scientists are moving beyond editing genes to writing entirely new genetic code and creating organisms that have never existed. These are almost certainly patentable under `Chakrabarty`, but they raise profound ethical questions that could eventually lead to legislative limits on what can be patented.
• Artificial Intelligence in Drug Discovery: What happens when an AI, not a human, discovers a new therapeutic use for a natural compound? Can a method discovered by an AI be patented? The law currently requires a human inventor. The rise of AI challenges the very definition of “invention” and “ingenuity” that underpins the patent system.
• A Return to Congress? For decades, the courts have shaped the `35_usc_101` exceptions. Many in the `intellectual_property` community, frustrated by the uncertainty, are calling for Congress to step in and pass new legislation that clarifies the boundaries of patentable subject matter for the 21st century. Whether this will happen remains one of the biggest questions in patent law.

• `* 35_usc_101`: The section of U.S. patent law that defines what categories of inventions are eligible for a patent.
• `* cDNA`: Complementary DNA; a synthetic DNA molecule created from an mRNA template, which lacks the non-coding regions (introns) of natural DNA.
• `* composition_of_matter`: One of the four categories of patentable inventions, referring to chemical compositions and mixtures of ingredients.
• `* invention`: A new, useful, and non-obvious device, method, or composition that is the product of human ingenuity.
• `* intellectual_property`: A category of property that includes intangible creations of the human intellect, such as patents, copyrights, and trademarks.
• `* non-obviousness`: A legal requirement for a patent that the invention not be an obvious development to someone with ordinary skill in the relevant field.
• `* novelty`: A legal requirement that an invention must be new and not previously known to the public to be patentable.
• `* office_action`: A formal communication from a USPTO patent examiner rejecting the claims in a patent application.
• `* patent`: A government grant giving an inventor the exclusive right to make, use, and sell their invention for a limited time.
• `* patent_claim`: The formal legal definition at the end of a patent application that specifies the exact boundaries of the invention to be protected.
• `* patent_eligibility`: The threshold inquiry of whether an invention falls into a category that can be patented under `35_usc_101`.
• `* prior_art`: The body of public knowledge, including existing patents and publications, that is relevant to an invention's novelty and non-obviousness.
• `* uspto`: The United States Patent and Trademark Office; the federal agency responsible for granting U.S. patents.
• `* utility`: A legal requirement that an invention must be useful for some practical purpose to be patentable.

• `* patent_law`
• `* intellectual_property`
• `* copyright`
• `* trademark`
• `* trade_secret`
• `* biotechnology_law`
• `* 35_usc_101`